fbpx

U.S. Anti-Doping Agency (USADA)

Global DRO logo in whiteSearch Medications & Ingredients

Athlete Login >

GlobalDRO >
Medication Search >

U.S. Track & Field Athlete Vikas Patel Accepts Sanction for Anti-Doping Rule Violations

December 27, 2017

USADA announced today that Vikas Patel of Bloomington, Ind., an athlete in the sport of track and field, has accepted a four-year sanction for his anti-doping rule violations while a member of the Thinking Feet Track Club.

In 2016, USADA obtained non-analytical evidence that Patel, 22, used and possessed a dietary supplement, which clearly indicated that it contained ostarine, from June 2015 through July 2015. Ostarine is a non-Specified Substance in the class of Anabolic Agents and is prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic Committee National Anti-Doping Policies, and the International Association of Athletics Federations Anti-Doping Rules, all of which have adopted the World Anti-Doping Code (the Code) and the World Anti-Doping Agency Prohibited List.

Ostarine, also known as MK-2866 and Enobosarm, is a non-FDA approved selective androgen receptor modulator (SARM) that is illegally sold in the United States and worldwide as a performance-enhancing substance. Ostarine is not currently available as a prescription medication in any country, and its unauthorized use may carry serious side effects. Nonetheless, ostarine has been found as a declared and undeclared ingredient in many dietary supplements sold in the United States, which has prompted the U.S. Food and Drug Administration (FDA) to issue warning letters to specific dietary supplement manufacturers stating that ostarine is an unapproved new drug and that selling the drug is in violation of the Federal Food, Drug, and Cosmetic Act. More information about the risks of ostarine can be found through a USADA athlete advisory.

Patel’s four-year period of ineligibility began on January 27, 2017, the date he first admitted his anti-doping rule violations. In addition, Patel has been disqualified from all competitive results obtained on and subsequent to June 1, 2015, the approximate date he first began using a prohibited substance, including forfeiture of any medals, points and prizes. To date, Patel is one of nine individuals affiliated with the Thinking Feet Track Club to have accepted a sanction during the course of USADA’s investigation.

In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, USADA manages a drug reference hotline, Global Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.

Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at playclean@usada.org, by phone at 1-877-Play Clean  (1-877-752-9253) or by mail at the address below.

USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.

Scroll to Top